Cyclo Therapeutics, Inc. (NASDAQ:CYTH) Short Interest Down 19.6% in March

Cyclo Therapeutics, Inc. (NASDAQ:CYTH) saw a significant drop in short interest in March. As of March 15th, there was short interest totalling 434,100 shares, a drop of 19.6% from the February 28th total of 539,600 shares. Based on an average daily trading volume, of 1,420,000 shares, the short-interest ratio is presently 0.3 days. Approximately 3.6% of the shares of the stock are short sold.

Cyclo Therapeutics Stock Performance

Shares of NASDAQ:CYTH opened at $0.72 on Monday. The stock has a market capitalization of $23.72 million, a P/E ratio of -0.80 and a beta of -0.57. Cyclo Therapeutics has a 12-month low of $0.55 and a 12-month high of $1.79. The stock’s 50-day moving average price is $0.79 and its 200-day moving average price is $0.73.

Institutional Investors Weigh In On Cyclo Therapeutics

An institutional investor recently bought a new position in Cyclo Therapeutics stock. Two Sigma Securities LLC purchased a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 42,541 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned approximately 0.15% of Cyclo Therapeutics at the end of the most recent quarter. 68.55% of the stock is owned by hedge funds and other institutional investors.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.